Anti-angiogenesis in prostate cancer: knocked down but not out. [electronic resource]
Producer: 20141217Description: 372-7 p. digitalISSN:- 1745-7262
- Angiogenesis Inhibitors -- therapeutic use
- Anilides -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Bevacizumab
- Clinical Trials, Phase III as Topic
- Humans
- Indoles -- therapeutic use
- Lenalidomide
- Male
- Neovascularization, Pathologic -- drug therapy
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds -- therapeutic use
- Prostatic Neoplasms -- blood supply
- Prostatic Neoplasms, Castration-Resistant -- blood supply
- Pyridines -- therapeutic use
- Pyrroles -- therapeutic use
- Quinazolines -- therapeutic use
- Quinolines -- therapeutic use
- Quinolones
- Receptors, Vascular Endothelial Growth Factor -- therapeutic use
- Recombinant Fusion Proteins -- therapeutic use
- Sorafenib
- Sunitinib
- Thalidomide -- analogs & derivatives
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Review
There are no comments on this title.
Log in to your account to post a comment.